J&J Secures Option on Sail’s In Vivo CAR-T Platform
Johnson & Johnson entered strategic agreements with Sail Biomedicines to advance an immune-mediated-disease program and Sail’s broader in vivo CAR-T platform. J&J will make $785 million in total initial payments, including a $465 million…
